Teva Canada launches generic Tobi

TORONTO — Teva Canada on Thursday announced the launch of its generic of Tobi (tobramycin) inhalation solution. The drug is a respiratory antibiotic indicated to manage chronic pulmonary Pseudomonas aeruginosa infections in patients with cystic fibrosis. 

 

Tobi’s annual sales in Canada were $9.5 million for the 12 months ended November 2015, according to IMS Brogan. The drug is available in 60 mg/ml inhalation solution in 56 x 5-ml ampoules. 

 

“As the sole generic supplier of Tobramycin Inhalation Solution we endeavour to play an active role in supplying patients with a lower cost option to help facilitate the medical treatment of this infection,” Teva Canada general manager Doug Sommerville said.